Meenakshi Rajwanshia, Anjali Sharmab & Vandana Nuniaa*
aDepartment of Zoology, University of Rajasthan, Jaipur, Rajasthan, India
bDepartment of Pathology, BMCHRC Jaipur, Rajasthan, India
Received : 07th May, 2023 ; Revised : 07th June, 2023
DOI:-https://doi.org/10.5281/zenodo.11930274
Abstract– Prostate cancer (PCa) ranks as the second most prevalent cancer among males worldwide and Androgen deprivation therapy (ADT) stands as a crucial treatment in managing PCa. However, patients commonly develop resistance to ADT within 2-3 years, posing a significant challenge to its effectiveness. This resistance greatly impacts the success of ADT administration. The intricate nature of PCa is evident through its extensive array of metabolic and functional alterations within affected tissue, showcasing a broad spectrum of underlying mechanisms and drivers. Metabolites associated with PCa, can be evaluated with the application of H Nuclear Magnetic Resonance (NMR) spectroscopy. NMR metabolomics helps to understand the alteration in metabolite concentration in various biological samples. NMR metabolomics can also give information of therapeutic response in PCa patients. An integral feature of PCa lies in its altered lipid metabolism, leading to the accumulation of acyl carnitines due to metabolic dysregulation. Notably, the elevation of palmitoyl carnitine, a long-chain acyl carnitine, has been observed in PCa patients. Analyses of serum samples from PCa patients who do not respond to ADT (ANR) exhibit elevated levels of palmitoyl carnitine compared to both PCa patients responsive to ADT (AR) and healthy control subjects. This study highlights the potential of palmitoyl carnitine as a marker for evaluating ADT response in PCa patients.
Key words: prostate cancer, metabolomics, metabolism, ADT, NMR spectroscopy
Be First to Comment